Cell & Gene Therapy CDMOs — Ranked by Signal Score · 2026
Cell & Gene Therapy manufacturers on CDMO Signal: 105 listed. 14 are fully evidenced (all four Signal Score pillars and at least one ClinicalTrials.gov match). The highest Signal Scores in that fully evidenced set are Bristol Myers Squibb (CGT Mfg) (in-house manufacturer, Signal Score 87), Novartis (in-house manufacturer, Signal Score 85.4) and City of Hope (T Cell Manufacturing) (academic or national centre, Signal Score 84). Outside that set, higher Signal Scores on this list include Pharmaron (Signal Score 86.9), FUJIFILM Diosynth Biotechnologies (Signal Score 86.7) and Charles River Laboratories (Signal Score 86.3). A higher score there is not a fully evidenced record. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology.
Cell & Gene Therapy CDMOs with the most regulatory evidence on file
Cell and gene therapy manufacturing spans two adjacent product classes: living cell products (CAR-T, TCR, NK, stem cell therapies) and the viral vectors used to genetically modify them (AAV, lentiviral, adenoviral). The two are tightly coupled in ex vivo cell engineering — a lentiviral vector CDMO supplies the vector that a cell therapy CDMO uses to modify patient T cells for CAR-T. Sponsors running integrated programs benefit from CDMOs covering both, and the ranking below aggregates that combined view.
For platform-specific rankings, use the dedicated pages: <a href="/modality/cell-therapy">Cell Therapy CDMOs</a>, <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>, <a href="/modality/gene-therapy">Gene Therapy CDMOs</a> (vectors only, no cell processing).
FDA inspection outcomes across these CDMOs: 67 NAI (no action), 88 VAI (voluntary action), 5 OAI (official action). Leading inspection & GMP sites: United States (110), UNITED KINGDOM (64), Denmark (52), Austria (39), Germany (37).
Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score
Showing all operator types.
| # | CDMO | Signal Score | Quality | FDA · GMP | Last FDA inspection | Capacity | Programs |
|---|---|---|---|---|---|---|---|
| 1 |
BMS
|
87.0 | 97.2 | 8 insp · 2 GMP | 2026-04-28 · NAI | — | 585 programs |
| 2 |
PB
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
|
86.9 | 100.0 | 5 insp · 1 GMP | 2026-08-14 · NAI | Available | — |
| 3 |
FD
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Hiring · 20 open roles
|
86.7 | 100.0 | 0 insp · 35 GMP | None on file | — | |
| 4 |
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
86.3 | 99.2 | 9 insp · 11 GMP | 2026-05-01 · NAI | Limited | — |
| 5 |
|
85.4 | 97.4 | 17 insp · 51 GMP | 2026-06-24 · NAI | — | 135 programs |
| 6 |
KB
|
84.1 | 98.5 | 2 insp · 1 GMP | 2026-04-01 · VAI | Limited | — |
| 7 |
COH
|
84.0 | 97.3 | 3 insp · 0 GMP | 2025-08-20 · VAI | — | 213 programs |
| 8 |
AJ
San Diego, CA · Osaka, JP
|
83.5 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 9 |
TK
|
83.4 | 100.0 | 4 insp · 20 GMP | 2026-04-10 · NAI | — | 100 programs |
| 10 |
MN
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
|
83.1 | 99.2 | 3 insp · 4 GMP | 2025-11-25 · NAI | Limited | — |
| 11 |
RP
Keele, UK · Sodertalje, SE
|
82.9 | 100.0 | 0 insp · 3 GMP | None on file | — | — |
| 12 |
WB2
Shanghai, CN · Wuxi, CN
|
82.7 | 99.6 | 1 insp · 4 GMP | 2026-07-03 · VAI | — | — |
| 13 |
MK
Darmstadt, DE · St. Louis, MO
Hiring · 8 open roles
Fully evidenced
Also makes its own products
|
81.9 | 98.8 | 2 insp · 2 GMP | 2025-04-28 · VAI | — | 22 programs |
| 14 |
LB
|
81.6 | 100.0 | 2 insp · 0 GMP | 2026-09-18 · NAI | — | — |
| 15 |
SC
Prague, Czech Republic
|
81.6 | 100.0 | 0 insp · 5 GMP | None on file | — | — |
| 16 |
EF
Planegg, DE · San Diego, CA
|
81.6 | 100.0 | 7 insp · 0 GMP | 2026-05-15 · NAI | — | — |
| 17 |
NW
|
80.8 | 100.0 | 0 insp · 8 GMP | None on file | Available | — |
| 18 |
CF
Les Ulis, FR
|
80.3 | 100.0 | 0 insp · 4 GMP | None on file | — | — |
| 19 |
SG
|
80.3 | 100.0 | 3 insp · 0 GMP | 2025-02-20 · NAI | — | — |
| 20 |
BR
|
80.3 | 97.2 | 6 insp · 10 GMP | 2026-05-13 · VAI | — | — |
| 21 |
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
|
79.9 | 99.8 | 4 insp · 27 GMP | 2026-05-29 · NAI | Available | 2 programs |
| 22 |
SK
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
|
79.5 | 100.0 | — | None on file | Available | — |
| 23 |
BV
|
79.4 | 99.8 | 1 insp · 4 GMP | 2024-12-19 · VAI | — | — |
| 24 |
RC
|
79.3 | 96.8 | 1 insp · 1 GMP | 2025-01-21 · VAI | Available | — |
| 25 |
UM
Boston, MA
|
78.7 | 96.7 | 2 insp · 0 GMP | 2025-12-18 · VAI | — | — |
| 26 |
GZ
|
78.1 | 100.0 | 1 insp · 0 GMP | 2025-08-27 · NAI | Available | — |
| 27 |
AA
Rockville, MD · Alachua, FL · Munich, DE
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 28 |
NG
Leiden, NL
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 29 |
ET
Jumet, BE
|
78.1 | 100.0 | 0 insp · 4 GMP | None on file | — | — |
| 30 |
PG
Berlin, DE
|
78.1 | 100.0 | 0 insp · 4 GMP | None on file | — | — |
| 31 |
CE
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 32 |
XP
Bristol, United Kingdom
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 33 |
AD
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 2 GMP | None on file | — | — |
| 34 |
GP
San Diego, CA
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 35 |
TF
Plainville, MA · Alachua, FL · Cambridge, MA
Hiring · 299 open roles
Fully evidenced
|
77.6 | 93.2 | 19 insp · 10 GMP | 2026-06-30 · NAI | Available | 2 programs |
| 36 |
AG2
San Carlos, CA
|
77.6 | 98.8 | 1 insp · 0 GMP | 2025-04-18 · VAI | — | — |
| 37 |
CS
Los Angeles, CA
Hiring · 1 open role
Fully evidenced
Academic / national centre
|
77.3 | 92.9 | 2 insp · 0 GMP | 2025-03-14 · NAI | — | 34 programs |
| 38 |
VG
|
76.8 | 100.0 | 0 insp · 4 GMP | None on file | Available | — |
| 39 |
SY
Stirling, United Kingdom
|
76.8 | 100.0 | 1 insp · 8 GMP | 2025-01-31 · NAI | — | — |
| 40 |
CY
Toulouse, FR
|
76.8 | 100.0 | 0 insp · 2 GMP | None on file | — | — |
| 41 |
CN
Luxembourg, LU
|
76.8 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 42 |
HH
London, United Kingdom
|
76.8 | 100.0 | 0 insp · 4 GMP | None on file | — | — |
| 43 |
FH
|
76.3 | — | — | None on file | — | 454 programs |
| 44 |
OX
Oxford, United Kingdom
Hiring · 4 open roles
Fully evidenced
Also makes its own products
|
76.2 | 100.0 | 2 insp · 13 GMP | 2024-06-17 · NAI | Available | 7 programs |
| 45 |
|
76.1 | 77.3 | 24 insp · 39 GMP | 2026-05-22 · VAI Warning letter 2025-11-20 |
— | — |
| 46 |
BC
|
75.7 | 93.1 | 7 insp · 2 GMP | 2025-09-03 · VAI | — | — |
| 47 |
BY
|
75.2 | — | — | None on file | — | 126 programs |
| 48 |
CI
Cincinnati, OH
Hiring · 2 open roles
Fully evidenced
Academic / national centre
|
75.1 | 99.6 | 2 insp · 0 GMP | 2025-02-05 · NAI | — | 1 program |
| 49 |
NR
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Hiring · 100+ open roles
Fully evidenced
|
73.6 | 95.6 | 1 insp · 0 GMP | 2025-01-21 · VAI | Available | 9 programs |
| 50 |
DH
|
73.0 | — | — | None on file | — | — |
| 51 |
MB
|
73.0 | 100.0 | 0 insp · 2 GMP | None on file | — | 8 programs |
| 52 |
|
72.8 | 86.6 | 11 insp · 8 GMP | 2025-09-29 · VAI | — | 1 program |
| 53 |
RT
|
71.1 | 100.0 | 0 insp · 4 GMP | None on file | — | 1 program |
| 54 |
BB
|
70.5 | — | — | None on file | — | — |
| 55 |
IU
|
66.3 | — | — | None on file | — | 49 programs |
| 56 |
EM
|
66.1 | — | — | None on file | — | 4 programs |
| 57 |
IO
|
65.9 | — | — | None on file | — | 31 programs |
| 58 |
CG
|
65.5 | — | — | None on file | — | — |
| 59 |
Piscataway, NJ / Nanjing, China
|
64.0 | — | — | None on file | — | — |
| 60 |
VE
Rockville, MD · Memphis, TN · Keele, United Kingdom
|
64.0 | — | — | None on file | — | — |
| 61 |
PBI
Pennington, NJ · Nanjing, CN
|
64.0 | — | — | None on file | — | — |
| 62 |
AN
Columbus, OH
|
63.0 | — | — | None on file | Available | — |
| 63 |
CT
|
63.0 | — | — | None on file | — | — |
| 64 |
RA
Stockholm, Sweden
|
63.0 | — | — | None on file | — | — |
| 65 |
HG
|
63.0 | — | — | None on file | — | — |
| 66 |
SM
|
63.0 | — | — | None on file | — | — |
| 67 |
EA
Singapore, Singapore
|
63.0 | — | — | None on file | — | — |
| 68 |
IP
Ahmedabad, India
|
62.3 | 68.9 | 3 insp · 5 GMP | 2025-09-16 · OAI Warning letter 2026-03-30 |
— | — |
| 69 |
AB
Research Triangle, NC · San Sebastian, ES
Also makes its own products
|
61.8 | — | — | None on file | — | 10 programs |
| 70 |
OB
Hamilton, ON
|
61.5 | — | 0 insp · 2 GMP | None on file | — | — |
| 71 |
GF
Alameda, CA and South San Francisco
|
61.5 | — | — | None on file | Available | — |
| 72 |
FB
|
61.2 | — | — | None on file | 3 programs | |
| 73 |
MA
College Station, TX
|
59.0 | — | — | None on file | Available | — |
| 74 |
CL
|
59.0 | — | — | None on file | Available | — |
| 75 |
VB
Philadelphia, PA
|
59.0 | — | — | None on file | — | — |
| 76 |
MS
Princeton, NJ
|
59.0 | — | — | None on file | — | — |
| 77 |
WB
Madison, WI
|
59.0 | — | — | None on file | — | — |
| 78 |
EB
|
59.0 | — | — | None on file | — | — |
| 79 |
OR
|
59.0 | — | — | None on file | — | — |
| 80 |
CC
|
59.0 | — | — | None on file | — | — |
| 81 |
MX
|
59.0 | — | — | None on file | — | — |
| 82 |
CP
|
59.0 | — | — | None on file | — | — |
| 83 |
C3
|
59.0 | — | — | None on file | — | — |
| 84 |
EX
|
59.0 | — | — | None on file | — | — |
| 85 |
CZ
Cologne, Germany
|
59.0 | — | — | None on file | — | — |
| 86 |
AS
|
59.0 | — | — | None on file | — | — |
| 87 |
VM
Cambridge, MA
|
59.0 | — | — | None on file | — | — |
| 88 |
AP
Milpitas, CA
|
59.0 | — | — | None on file | — | — |
| 89 |
AM
Gerenzano, Italy
|
59.0 | — | — | None on file | — | — |
| 90 |
HX
|
59.0 | — | — | None on file | — | — |
| 91 |
CTP
Melbourne, Australia
|
59.0 | — | — | None on file | — | — |
| 92 |
SS
Bloomington, IN
|
59.0 | — | — | None on file | — | — |
| 93 |
PO
|
58.7 | — | — | None on file | — | 6 programs |
| 94 |
TR
Kusatsu, Shiga Prefecture, Japan
|
57.9 | — | — | None on file | — | 8 programs |
| 95 |
TG
|
57.8 | — | — | None on file | — | 1 program |
| 96 |
KC
|
56.5 | — | — | None on file | — | — |
| 97 |
UB
|
56.5 | — | — | None on file | — | — |
| 98 |
CV
Cologne, Germany
|
56.5 | — | — | None on file | — | — |
| 99 |
CX
|
56.5 | — | — | None on file | — | — |
| 100 |
GC
Yongin, KR
|
56.5 | — | — | None on file | — | — |
| 101 |
CH
Seongnam, KR
|
56.5 | — | — | None on file | — | — |
| — |
Germany
|
Profiled | — | 2 insp · 2 GMP | 2023-09-08 · VAI | — | — |
| — |
Chongqing, China
|
Profiled | — | 1 insp · 0 GMP | 2024-03-29 · NAI | — | — |
| — |
|
Profiled | — | 3 insp · 0 GMP | 2025-10-29 · VAI | — | — |
| — |
San Diego, California, USA
|
Profiled | — | — | None on file | — | — |
What to evaluate in a Cell & Gene Therapy CDMO
Which CDMOs integrate cell therapy processing with viral vector supply?
How is cell therapy CDMO scoring different from vector CDMO scoring?
How CDMO Signal aggregates the cell and gene therapy view
What differentiates an approved-program cell and gene therapy CDMO?
Cell & Gene Therapy CDMOs — Frequently Asked Questions
For a European shortlist, see the best cell and gene therapy CDMO in Europe.